title: Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients.
abstract: OBJECTIVE
  To investigate the regulation of interferon-alpha (IFN-alpha) receptor expression in metastatic renal cell carcinoma (RCC) after IFN-alpha administration.
  
  
  METHODS
  Blood sampling was carried out in eight patients with metastatic RCC and six healthy volunteers. Flow-cytometric analysis using a monoclonal antibody against the active subunit of the type-I IFN-alpha receptor (IFNAR2) was carried out to examine the circadian rhythm of IFNAR2 expression in peripheral blood mononuclear cells (PBMC) as well as its downregulation after IFN-alpha administration.
  
  
  RESULTS
  According to its circadian rhythm IFNAR2 in PBMC had a peak expression at night. Once IFN-alpha is administered, IFNAR2 levels in PBMC showed downregulation within 48 h and recovered within another 48 h.
  
  
  CONCLUSIONS
  Our findings might support the establishment of an optimal schedule for IFN-alpha administration.
authors.affiliation: Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shiba
authors.forename: Norio
authors.initials: N
authors.lastname: Nonomura
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nakai
authors.forename: Masashi
authors.initials: M
authors.lastname: Nakayama
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takayama
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Inoue
authors.forename: Akira
authors.initials: A
authors.lastname: Tsujimura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Nishimura
authors.forename: Akihiko
authors.initials: A
authors.lastname: Okuyama
mesh_terms: D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000188:drug therapy*; D002940:Circadian Rhythm; D015536:Down-Regulation; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000097:blood* / Q000188:drug therapy*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D053633:Receptor, Interferon alpha-beta / Q000096:biosynthesis* / Q000187:drug effects
chemical_list: C508033:IFNAR2 protein, human; D007155:Immunologic Factors; D016898:Interferon-alpha; D053633:Receptor, Interferon alpha-beta